MSH6 and renal pelvis/ureter urothelial carcinoma: According to recent studies, it is a well-known fact that the proportion of UTUC patients with MSH2/MSH6 loss (particularly MSH2 germline mutations) is more than patients with other types of MMR loss (15, 26).